Merck Maintains Dividend as MRK Stock Navigates Pharmaceutical Pipeline and Oncology Growth
Merck continues to deliver steady dividend payments while investing heavily in its pharmaceutical pipeline. The company’s oncology franchise, led by Keytruda, generates billions in annual revenue. For income investors, MRK stock offers a pharmaceutical dividend
